High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Case-Control Studies
Disease Progression
Disease Susceptibility
/ immunology
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
/ drug therapy
Multiple Myeloma
/ drug therapy
Neutrophils
/ immunology
Phagocytosis
/ genetics
STAT3 Transcription Factor
/ metabolism
Signal Transduction
/ genetics
Tumor Escape
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 02 2020
06 02 2020
Historique:
received:
25
07
2019
accepted:
06
01
2020
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, we identified a total of 551 upregulated and 343 downregulated genes in MM-HDN, involved in chemokine signaling pathway and FC-gamma receptor mediated phagocytosis conveying in the activation of STAT proteins. In a series of 60 newly diagnosed MM and 30 MGUS patients, by flow-cytometry we found that HDN from MM, and to a lesser extend MGUS, had an up-regulation of the inducible FcγRI (also known as CD64) and a down-regulation of the constitutive FcγRIIIa (also known as CD16) together with a reduced phagocytic activity and oxidative burst, associated to increased immune-suppression that could be reverted by arginase inhibitors in co-culture with lymphocytes. In 43 consecutive newly-diagnosed MM patients, who received first-line treatment based on bortezomib, thalidomide and dexamethasone, high CD64 could identify at diagnosis patients with inferior median overall survival (39.5 versus 86.7 months, p = 0.04). Thus, HDNs are significantly different among healthy, MGUS and MM subjects. In both MGUS and MM neutrophils may play a role in supporting both the increased susceptibility to infection and the immunological dysfunction that leads to tumor progression.
Identifiants
pubmed: 32029833
doi: 10.1038/s41598-020-58859-x
pii: 10.1038/s41598-020-58859-x
pmc: PMC7005058
doi:
Substances chimiques
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1983Références
Oncotarget. 2017 Mar 21;8(12):18792-18801
pubmed: 27852046
Ann Intern Med. 1982 Jan;96(1):47-50
pubmed: 6976144
Blood. 2013 Apr 11;121(15):2975-87
pubmed: 23321256
Cancer Res. 2012 Mar 15;72(6):1373-83
pubmed: 22282665
Immunol Rev. 2016 Sep;273(1):312-28
pubmed: 27558343
Oncoimmunology. 2015 May 26;4(11):e1047580
pubmed: 26451323
Clin Transplant. 2018 Sep;32(9):e13359
pubmed: 30053318
Cancer Lett. 2016 Feb 1;371(1):117-24
pubmed: 26639197
Front Immunol. 2018 Oct 02;9:2171
pubmed: 30356867
J Immunol. 2014 Apr 15;192(8):3470-3
pubmed: 24639346
Semin Immunol. 2018 Feb;35:19-28
pubmed: 29254756
Arthritis Res Ther. 2009;11(1):R6
pubmed: 19144150
Mediators Inflamm. 2008;2008:202646
pubmed: 18604302
Eur J Haematol. 1998 Aug;61(2):140-4
pubmed: 9714528
Curr Opin Pharmacol. 2011 Aug;11(4):397-403
pubmed: 21741310
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
J Leukoc Biol. 2015 Oct;98(4):489-96
pubmed: 25632045
Biomed Res Int. 2014;2014:198539
pubmed: 25013764
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1444-1448
pubmed: 29070122
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Clin Lab Anal. 2016 Nov;30(6):1208-1213
pubmed: 27239981
Blood. 2013 Feb 28;121(9):1563-73
pubmed: 23293080
J Immunol. 2017 May 15;198(10):4129-4139
pubmed: 28356386
Blood. 2009 May 28;113(22):5418-22
pubmed: 19234139
Br J Haematol. 2007 Sep;138(5):563-79
pubmed: 17686051
Cell Immunol. 2004 Apr;228(2):130-7
pubmed: 15219464
Shock. 2001 Aug;16(2):102-8
pubmed: 11508860
Tuberculosis (Edinb). 2018 Jul;111:135-142
pubmed: 30029898
Nat Commun. 2018 Dec 3;9(1):4832
pubmed: 30510245
Cell Death Dis. 2019 Sep 20;10(10):704
pubmed: 31541083
Blood Adv. 2017 Jun 20;1(15):1056-1066
pubmed: 29296748
Br J Haematol. 2010 Sep;150(5):543-53
pubmed: 20629663
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Front Immunol. 2014 Jun 03;5:257
pubmed: 24917865
Exp Hematol. 2016 May;44(5):342-351.e5
pubmed: 26774385
J Oncol Pharm Pract. 2012 Jun;18(2):257-63
pubmed: 21859744
J Immunol. 2010 Sep 1;185(5):2927-34
pubmed: 20679530
Genes Immun. 2019 Sep;20(7):589-598
pubmed: 30880333
Oncotarget. 2015 Apr 30;6(12):10532-47
pubmed: 25871384
JCI Insight. 2019 Apr 23;5:
pubmed: 31013254
Acta Haematol. 2018;140(3):146-156
pubmed: 30253397
Pediatr Emerg Care. 2008 Nov;24(11):745-8
pubmed: 18955911
Leuk Lymphoma. 2014 Dec;55(12):2893-900
pubmed: 24625328
Biochem J. 2011 Jan 15;433(2):383-91
pubmed: 21029045
Scand J Haematol. 1976 Jul;17(1):62-70
pubmed: 959776
Haematologica. 2014 Oct;99(10):1605-10
pubmed: 24972771
Cancer. 2003 May 15;97(10):2440-52
pubmed: 12733143
Haematologica. 2012 Jun;97(6):854-8
pubmed: 22180421
Methods Mol Biol. 2020;2087:243-260
pubmed: 31728997
J Biol Chem. 1991 Nov 25;266(33):22079-82
pubmed: 1834666
Oncotarget. 2016 Dec 27;7(52):85764-85775
pubmed: 26967390
Cancer Biomark. 2018;22(1):43-48
pubmed: 29562497
J Leukoc Biol. 2007 Aug;82(2):237-43
pubmed: 17502339
Semin Oncol. 1986 Sep;13(3):282-90
pubmed: 3532328
J Immunol. 1998 Jan 15;160(2):911-9
pubmed: 9551929
J Clin Oncol. 2005 Dec 20;23(36):9219-26
pubmed: 16275935
Blood. 2011 May 5;117(18):4701-5
pubmed: 21292778
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
Oncotarget. 2015 Dec 22;6(41):43992-4004
pubmed: 26556857
Leukemia. 2015 Nov;29(11):2173-83
pubmed: 25987254
J Clin Invest. 2013 Oct;123(10):4464-78
pubmed: 24091328
Ann Hematol. 2015 Nov;94(11):1875-83
pubmed: 26223359
Front Oncol. 2014 Dec 08;4:348
pubmed: 25538892
FEBS Lett. 1996 May 20;386(2-3):239-42
pubmed: 8647290
Nat Immunol. 2019 Dec;20(12):1594-1602
pubmed: 31745337
J Immunol. 2011 Aug 15;187(4):1578-90
pubmed: 21753152
J Clin Invest. 2018 Jun 1;128(6):2487-2499
pubmed: 29558366
Expert Rev Mol Diagn. 2018 Jul;18(7):675-683
pubmed: 29707981
Scand J Immunol. 2010 Dec;72(6):540-7
pubmed: 21044128
Immunobiology. 2017 Jan;222(1):82-88
pubmed: 26874580
Blood. 1992 Feb 1;79(3):735-44
pubmed: 1531037
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Clin Vaccine Immunol. 2011 Jun;18(6):969-77
pubmed: 21508164
Blood. 2017 Apr 6;129(14):1991-2001
pubmed: 28143882
Blood Cancer J. 2017 Dec 15;7(12):649
pubmed: 29242558
J Clin Pathol. 1995 Mar;48(3):260-6
pubmed: 7730490
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Eur J Haematol. 2018 Jul;101(1):21-27
pubmed: 29569379
J Leukoc Biol. 2017 Aug;102(2):343-349
pubmed: 28264904
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Trends Immunol. 2019 Mar;40(3):228-242
pubmed: 30777721
J Biol Chem. 2011 Jul 8;286(27):24113-24
pubmed: 21586572
Oncoimmunology. 2015 May 7;4(6):e1008850
pubmed: 26155424
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S408-15
pubmed: 16237639
Cell Mol Life Sci. 2013 Oct;70(20):3813-27
pubmed: 23423530
Ann Surg. 2010 Jan;251(1):120-6
pubmed: 20032720
Sci Rep. 2019 Mar 1;9(1):3245
pubmed: 30824741
Semin Immunopathol. 2013 Jul;35(4):377-94
pubmed: 23553214
Genes Immun. 2013 Sep;14(6):347-55
pubmed: 23657238
Int J Mol Sci. 2019 Jul 19;20(14):
pubmed: 32565533
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Blood. 2010 Jan 14;115(2):335-43
pubmed: 19890092
Biochem Biophys Res Commun. 1990 Jul 31;170(2):582-8
pubmed: 2143376
J Immunol. 2013 Apr 1;190(7):3815-23
pubmed: 23460744